IDH1 Peptide Vaccine for Recurrent Grade II Glioma
Status:
Active, not recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
Potential subjects with progressive Grade II primary brain tumor that have IDH1 positive
testing from the primary tumor (initial diagnosis) will be offered this treatment study in
order to test the safety of the PEPIDH1M vaccine in combination with standard chemotherapy
(temozolomide).